

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, Website- www.raymedlab.com

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

Date: 08.02.2021

To,  
Head Listing Compliance,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

**Security Code: 531207**

**Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today i.e. **Monday, 8<sup>th</sup> February, 2021** (commenced at 03:00 P.M and concluded at 03:45 P.M.) has inter alia approved and passed the following resolutions:

1. **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended on December 31, 2020.
2. Taking note of the **Limited Review Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended on December 31, 2020.
3. Taking Note for the period ended on 31st December, 2020:
  - i) Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015
  - ii) Intimation for Closure of Trading Window for Designated Persons as required under SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018.
  - iii) Certificate of Non-Applicability of Compliance with Report on Corporate Governance as required under Regulation 27(2) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
  - iv) The Reconciliation of Share Capital Audit Report under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, Website- www.raymedlab.com

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

- v) Shareholding pattern pursuant to Regulation 31 of the (Listing Obligations and Disclosure Requirements) Regulation 2015
  - vi) Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018
4. Taking note of Certificate of Non-Applicability of Disclosure of Related Party Transactions on a consolidated basis as required under Regulation 23(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half year ended on 30th September, 2020.
5. Taking note & discussion on Notice received from BSE via Email dated November 20, 2020 and December 07, 2020 w.r.t Regulation 6(1) of SEBI (LODR) Regulations, 2015- Non-compliance with requirement to appoint a qualified company secretary as the compliance officer for the quarter ended September 30, 2020.

Director's Comment: Efforts have been made for the appointment of a Whole time Company Secretary but the management was unable to appoint suitable candidate for the said post. Further, in the wake of the global COVID-19 pandemic and in view nationwide lockdown announced by the Government of India (GOI) to control the spread of COVID-19, the Company's official works was disrupted. Hence, the Company was facing difficulties in undertaking timely compliances of various applicable laws. Further the Company has finalized a candidate and appointed Mr. Akbar Mehtab as Company Secretary w.e.f. 29.09.2020. The Company has also made a request for Waiver of Penalty imposed by the Stock exchange for Non-compliance of Regulation 6(1) of SEBI (Listing Obligations & Disclosure requirements) Regulations, 2015.

Kindly take the above information on your records.

Thanking you,

Yours Sincerely,  
**For Raymed Labs Limited**

**AJAI** Digitally signed  
by AJAI GOYAL  
**GOYAL** Date: 2021.02.08  
15:47:20 +05'30'

**Ajai Goyal**  
**Whole time Director**  
**DIN: 02636418**



# A. Kay Mehra & Co.

**CHARTERED ACCOUNTANTS**

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

---

## LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31<sup>TH</sup> DECEMBER, 2020

To


**The Board of Directors**

**Raymed Labs Limited**

103 Emperor 1, Supertech Emerald Court,

Sector 93A, Noida - 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the period ended on 31<sup>th</sup> December, 2020, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial



results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay. Mehra & Co.  
Chartered Accountants  
(F.R.N. 050004C)



Date: February 08, 2021

Place: Noida

UDIN: 21501957AAAAEU3608

Signature  
Deepak Suneja  
(Partner)

(Membership NO- 501957)

**Raymed Labs Limited**

Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,  
Uttar Pradesh, CIN: L24111UP1992PLC014240  
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com  
Tel: 0120-2426900, 9412700300

**Statement of Standalone Unaudited Financial Results for the Quarter ended December 31, 2020**

Particulars	Amt. (In Lacs)					
	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2020	30-09-2020	31-12-2019	12/31/2020	12/31/2019	3/31/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I. Revenue from Operations</b>	0.00	0.00	0.00	0.00	0.00	0.00
<b>II. Other Income</b>	0.00	0.33	0.33	0.66	0.99	1.32
<b>III. Total Income (I +II)</b>	<b>0.00</b>	<b>0.33</b>	<b>0.33</b>	<b>0.66</b>	<b>0.99</b>	<b>1.32</b>
<b>IV. Expenses</b>						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.65	0.23	0.23	1.10	1.38	1.60
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.14	0.14	0.15	0.43	0.45	0.60
Other Expenses	0.57	0.14	2.58	1.22	4.20	4.69
<b>Total Expenses (IV)</b>	<b>1.36</b>	<b>0.51</b>	<b>2.96</b>	<b>2.75</b>	<b>6.03</b>	<b>6.89</b>
<b>V. Profit/(Loss) before exceptional items and tax (III-IV)</b>	<b>-1.36</b>	<b>-0.18</b>	<b>-2.63</b>	<b>-2.09</b>	<b>-5.04</b>	<b>-5.57</b>
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII. Profit/(Loss) before tax (V-VI)</b>	<b>-1.36</b>	<b>-0.18</b>	<b>-2.63</b>	<b>-2.09</b>	<b>-5.04</b>	<b>-5.57</b>
<b>VIII. Tax Expense</b>						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
<b>IX. Profit/(Loss) for the period from continuing operations (VII-VIII)</b>	<b>-1.36</b>	<b>-0.18</b>	<b>-2.63</b>	<b>-2.09</b>	<b>-5.04</b>	<b>-5.57</b>
<b>X. Profit/(Loss) from discontinued operations</b>			-		-	
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XIII. Profit/(Loss) for the period (IX+XII)</b>	<b>-1.36</b>	<b>-0.18</b>	<b>-2.63</b>	<b>-2.09</b>	<b>-5.04</b>	<b>-5.57</b>
<b>XIV. Other Comprehensive Income</b>						
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>XV. Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the Period)</b>	<b>-1.36</b>	<b>-0.18</b>	<b>-2.63</b>	<b>-2.09</b>	<b>-5.04</b>	<b>-5.57</b>
<b>XVI. Paid-up Equity Capital (Face Value of Rs. 10 each)</b>	42.735	42.735	42.735	42.735	42.735	42.735
<b>XVII. Earnings per equity share (for continuing operation):</b>						
(1) Basic	-0.0318	-0.0041	-0.0615	-0.0489	-0.1179	-0.1303
(2) Diluted	-0.0318	-0.0041	-0.0615	-0.0489	-0.1179	-0.1303
<b>XVIII. Earnings per equity share (for discontinued operation):</b>						
(1) Basic	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
(2) Diluted	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
<b>XIV. Earnings per equity share (for discontinued &amp; continuing operations)</b>						
(1) Basic	-0.0318	-0.0041	-0.0615	-0.0489	-0.1179	-0.1303
(2) Diluted	-0.0318	-0.0041	-0.0615	-0.0489	-0.1179	-0.1303

**Notes:**

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 8th February, 2021. The Statutory Auditors have carried out their limited review of the above results.

(2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification

(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

(6) The company has considered the possible effects that may result for the pandemic relating to COVID 19 on its business operations and financial position using internal & external factors known to the management upto the approval of financial results, There is no significant impact on the carrying amount of its assets and financial results and management concludes that no material uncertainty exists about the company's ability to continue as a going concern and accordingly financial results have been prepared using going concern assumption.

For Raymed Labs Limited

AJAI  
GOYAL

Digitally signed by  
AJAI GOYAL  
Date: 2021.02.08  
15:47:57 +05'30'

Ajai Goyal  
Wholetime Director  
DIN: 02636418

Date:08/02/2021  
Place : NOIDA